WHO Sounds Warning Over Severe Lack of Obesity Injections
Less than a tenth of patients that would benefit from obesity jabs including Wegovy can access them, caution the global health agency as it publishes its first recommendations on the drugs.
Given in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to this class of drugs.
Based on projections, more than two billion are projected to be living with obesity by 2030 without intervention.
"The new guidelines acknowledges that excess weight is a long-term condition that can be managed with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are major hurdles to widespread availability to the injections that can assist patients in reducing significant weight, notes the body.
GLP-1 Therapy Scarcity
Even in the current best projected case, the production of these medications could only cover about 100 million people – under 10% of eligible patients, according to the health organization.
The recommendation urges countries and companies to widen availability, via measures including patent sharing.
The intellectual property rights on semaglutide – the core component of a leading brand – is due to expire in a number of countries in 2026.
How Weight-Loss Drugs Function
The injections imitate a body's own hormone to delay gastric emptying, suppress the appetite and increase the sense of being full so individuals consume fewer calories.
Patients usually see weight reduction after several weeks of commencing the regular doses.
Evidence indicates users may regain a significant portion a year later of halting the treatment, as their typical food cravings come back.
To be overweight or obese raises your likelihood for developing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and specific malignancies.
Excess weight affects individuals in every country and was linked to millions of fatalities worldwide in 2024, according to the health agency.
